People on the Move
Medivir
Nordic company Medivir, which has an annual turnover of around 500m Swedish Krona (€54m), has appointed a new President and CEO.
Niklas Prager will succeed Maris Hartmanis from September 1, 2014. He holds a Master of Science degree in Business Administration and Economics from the Stockholm School of Economics, and has worked as CEO of Pfizer AB, Envirotainer AB and Qbtech AB. He has also worked for Merck & Co. Prager has served as Chairman of the Board of BioPhausia, and was elected to the Board of Medivir in May 2014.
The company was founded in 1988 as a spin-off from AstraZeneca's antiviral research unit and develops drugs for infectious diseases. Medivir receives royalties from Johnson & Johnson’s global sales of the hepatitis C pharmaceutical, Olysio.